Company news
DIAGNOS inc. news in 2026
DIAGNOS inc.'s news releases, calls and decks from 2026, newest first.
DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics
October 20, 2026
DIAGNOS Provides an Update on Stock Warrants
October 6, 2026
DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System
September 28, 2026
DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026
September 14, 2026
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
August 13, 2026
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
July 27, 2026
DIAGNOS to Extend the Exercise Period of Stock Warrants
July 7, 2026
DIAGNOS Announces Shares for Debt Settlement
June 18, 2026
DIAGNOS Submits Modified and Updated Health Canada Licence Application for CARA System Platform
June 16, 2026
DIAGNOS Announces Grant of Stock Options and Adoption of Semi-Annual Reporting
June 12, 2026
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
June 5, 2026
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
June 3, 2026
DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
April 8, 2026
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
April 1, 2026
DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
March 5, 2026
Q3 2026 MD&A – Download as a PDF
February 25, 2026
Q3 2026 Financial Statements – Download as a PDF
February 25, 2026
Rapport de gestion T3-2026 – Télécharger le PDF
February 25, 2026
DIAGNOS: États financiers T3-2026 – Télécharger le PDF
February 25, 2026
DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
February 24, 2026
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
February 4, 2026
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
February 4, 2026
DIAGNOS Announces the Engagement of IBN
January 15, 2026
DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
January 13, 2026